Terconazole
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
Terconazole: Trichomonal vulvovaginitis
One-Sentence Summary
Terconazole is a topical triazole antifungal that is currently marketed in Canada. The TxGNN model predicts it may be effective for trichomonal vulvovaginitis (score 0.9986), but no clinical trials and no studies that directly examine this condition were found, so the prediction remains model-only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Trichomonal vulvovaginitis |
| TxGNN Prediction Score | 0.9986 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the data compiled for this report. Based on known pharmacology, terconazole is a triazole antifungal. It inhibits fungal lanosterol 14-alpha-demethylase (CYP51), which blocks ergosterol synthesis in the fungal cell membrane.
This mechanism does not carry over well to trichomonal infection. Trichomonas vaginalis is a protozoan, and it lacks ergosterol-dependent membrane biology comparable to fungi. No plausible mechanistic link to terconazole was identified. The very high TxGNN score most likely reflects the drug’s closeness to other genital-tract infection conditions in the model’s network, not a true pharmacological effect. Standard therapy for this infection is a nitroimidazole (metronidazole or tinidazole).
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10546257 | 1999 | Review | The Nurse Practitioner | General overview of lower genital tract infections of bacterial, fungal and protozoal origin, including symptoms and management. It does not report terconazole data for trichomonal infection. |
| 6617296 | 1983 | Review | Chemotherapy | Describes terconazole as a broad-spectrum triazole antifungal with strong in vitro activity against yeasts and filamentous fungi. It reports no activity against protozoa. |
Neither publication directly studies terconazole in trichomonal vulvovaginitis.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02247651 | TARO-TERCONAZOLE | Not specified | Not specified in the compiled data |
Terconazole has one valid single-ingredient licence in Canada, and the drug is marketed.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone. No clinical trials or direct studies support it, and the drug’s antifungal mechanism offers no plausible action against a protozoal pathogen. Established nitroimidazole therapy already exists for this infection.
To proceed, the following is needed:
- In vitro data showing any activity of terconazole against Trichomonas vaginalis
- Detailed mechanism-of-action data
- Package insert warnings and contraindications from Health Canada, which are needed for safety screening
- Preclinical or early clinical evidence directly addressing this condition before any further consideration
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.